Trial Profile

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tovorafenib (Primary) ; Tovorafenib (Primary) ; Carboplatin; Vinblastine; Vincristine
Indications Glioma
Focus Registrational; Therapeutic Use
Acronyms FIREFLY-2; LOGGIC
Sponsors Day One Biopharmaceuticals

02 Mar 2026 Planned End Date changed from 1 Mar 2030 to 1 Jun 2031.
02 Mar 2026 Planned primary completion date changed from 1 Feb 2026 to 1 Jun 2027.
12 Jan 2026 According to a Day One Biopharmaceuticals media release, company expected a data readout in mid-2027 and a potential regulatory approval targeted for 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com